Guarner J, Sánchez-Mejorada-Fernández G, del Río-Chiriboga C, Mohar A
División de Servicios Auxiliares de Diagnóstico y Tratamiento, Instituto Nacional de Cancerología (INC), México.
Salud Publica Mex. 1996 May-Jun;38(3):207-11.
To study the correlation between ALC and CD4 cell counts and to find alternative ways of counting CD4+ T-lymphocytes.
The double positivity for CD3/CD4 antibodies was measured in 175 consecutive HIV-positive patients using flow cytometry; in these cases a difference was made between counting cells that were positive for both antibodies vs those that were positive only to CD4. ALC and CD4 counts were also compared among 500 subjects infected with HIV, using linear regression analysis and comparing the number of dissimilar cases for counts below 200 cells/microliters and ALC counts lower than 1 500 and 2000 cells/microliters.
In the 175 cases measured by the CD3/CD4 antibody combination the mean percent was 13.8% and for total CD4 cells 14.2% (p = NS); the mean difference was 0.4% and the median 0.2%. For the 500 patients the mean ALC was 1 700 cells/microliters and the mean CD4 count was 219 cells/microliters; the correlation coefficient was 0.59.
These data suggest a poor correlation of ALC and CD4 cell counts, thus it is impossible to predict CD4 on the basis of ALC. This is the reason why it is necessary to measure CD4 cells separately. The difference between measuring double positive CD3/CD4 cells vs only CD4 positive cells was not significant. Our data suggest that the use of a single CD4 antibody may cut costs and still produce clinically useful information.
研究绝对淋巴细胞计数（ALC）与CD4细胞计数之间的相关性，并寻找计数CD4 + T淋巴细胞的替代方法。
使用流式细胞术对175例连续的HIV阳性患者检测CD3/CD4抗体的双阳性情况；在这些病例中，区分同时对两种抗体呈阳性的细胞与仅对CD4呈阳性的细胞。还对500例HIV感染受试者的ALC和CD4计数进行了比较，采用线性回归分析，并比较计数低于200个细胞/微升以及ALC计数低于1500和2000个细胞/微升的不同病例数。
在通过CD3/CD4抗体组合检测的175例病例中，平均百分比为13.8%，总CD4细胞的平均百分比为14.2%（p =无显著性差异）；平均差异为0.4%，中位数为0.2%。对于500例患者，平均ALC为1700个细胞/微升，平均CD4计数为219个细胞/微升；相关系数为0.59。
这些数据表明ALC与CD4细胞计数之间的相关性较差，因此无法根据ALC预测CD4。这就是需要单独检测CD4细胞的原因。检测双阳性CD3/CD4细胞与仅检测CD4阳性细胞之间的差异不显著。我们的数据表明，使用单一CD4抗体可能会降低成本，同时仍能产生临床有用的信息。
